MABPHARM-B

2181
0.4900.00% ( 0.000 )
Delay Closed: Nov 16, 16:08:00

Overview

MABPHARM-B (2181)

Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoi...

Open
0.490
High
0.490
Low
0.490
Prev. Close
0.490
Volume
0
Turnover
0
Avg Price
--
Bid/Ask Ratio
-14.29%
Amplitude
0.00%
52wk High
0.810
Volume Ratio
0.00
Turnover Ratio
--
52wk Low
0.310
HK Mkt Cap
2.02B
Market CapHKD
2.02B
P/ETTM
20.51
P/EDynamic
27.98
P/EStatic
--
EPSTTM
0.0239
EPSDynamic
0.0175
EPSStatic
--
BVPS
0.05
P/B
9.05
HK Shares
4.12B
Dividend YieldTTM
--
DividendTTM
--
Shares
4.12B
Min lot size
2,000
Currency
HKD

MABPHARM-B Analyst Rating

View more

Forecast & Rating

Jul 28, 2022
Price forecast
HK$1.50206.12%
Forecast & RatingHold
1analysts
  • Strong buy0.00%
  • Buy0.00%
  • Hold100.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Mabpharm staged a rebound from intraday lows, recovering from 0.365 HKD to close at 0.395 HKD in the afternoon session, down 5.95% from the previous close of 0.420 HKD. The turnaround was driven by the company's full-year net profit of 57.13 million RMB, marking a return to profitability, which attracted buying interest near the 52-week low. Despite the stock trading 55.11% below its 52-week high of 0.88 HKD and down 21% YTD, Q4 revenue surged 159.61% YoY to 207 million HKD, with net profit up 286.62% YoY, reflecting fundamental improvement. However, the stock remains below both its MA20 (0.402 HKD) and MA60 (0.437 HKD), suggesting lingering technical headwinds.

News